

# 1 **Impact of brain frailty on complications and outcomes**

## 2 **in acute ischemic stroke**

3 XiaoQing Cheng<sup>1</sup>, MD; Wu Cai<sup>#2</sup>, MD; ChuYan Li<sup>3</sup>,MM; Xi Shen<sup>4</sup>,MM; JiaNan Li<sup>5</sup>,MM;  
4 LiJun Huang<sup>6</sup>,MM; JinJing Tang<sup>1</sup>,BS; HuiMin Pang<sup>1</sup>,BS; BaiYan Luo<sup>1</sup>,BS; Ya Liu<sup>1</sup>, MM;  
5 QianChen<sup>7</sup>,MD; Lulu Xiao<sup>8</sup>,MD; WuSheng Zhu<sup>8</sup>,MD; ZeHong Cao<sup>9</sup>, PhD; XiaoYu  
6 Liu<sup>10</sup>,MD; LongJiang Zhang<sup>1</sup>,MD; XinDao Yin<sup>7</sup>, MD; ZhiQiang Zhang<sup>\*1</sup>, MD; Feng Shi <sup>\*9</sup>,  
7 PhD; Wei Xing<sup>\*11</sup>,MD ; GuangMing Lu<sup>1</sup>,MD

### 8 **Affiliations**

9  
10 1 Department of Medical Imaging, Nanjing Jinling Hospital, Nanjing University School of  
11 Medicine, Nanjing, Jiangsu 210002, China

12 2 Department of Radiology, The Second Affiliated Hospital of Soochow University,  
13 Suzhou, Jiangsu 215004, China

14 3 Department of Medical Imaging, Nanjing Jinling Hospital, XuZhou Medical University.  
15 Nanjing, Jiangsu 210002, China.

16 4 Department of Medical Imaging, Nanjing Jinling Hospital, Nanjing Medical University,  
17 Nanjing, Jiangsu 210002, China.

18 5 Department of Medical Imaging, Nanjing Jinling Hospital, Affiliated Hospital of Medical  
19 School, Nanjing University, Nanjing, Jiangsu 210002, China

20 6 Department of Medical Imaging, Nanjing Jinling Hospital, the First School of Clinical  
21 Medicine, Southern Medical University, Nanjing, Jiangsu 210002, China

22 7 Departments of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing,  
23 Jiangsu 210002, China

24 8 Department of Neurology, Nanjing Jinling Hospital, Nanjing University School of  
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Medicine, Nanjing, Jiangsu 210002, China

26 9 Department of Research and Development, Shanghai United Imaging Intelligence Co., Ltd.,

27 Shanghai 200232, China

28 10 Department of Radiology, Ganzhou People's Hospital, Ganzhou, Jiangxi 341000, China

29 11 Department of Radiology, Third Afliated Hospital of Soochow University, Changzhou,

30 Jiangsu 213000, China

31

32 **Short title:** Brain frailty impact in acute ischemic stroke

33

34 # XiaoQing Cheng , Wu Cai contributed equally to this work.

35

36 **Correspondence**

37 Wei Xing ; Co- correspondence: ZhiQiang Zhang and Feng Shi

38 Department of Radiology, Third Afliated Hospital of Soochow University, Changzhou,

39 Jiangsu 213000, China

40 E-Mail: suzhxingwei@suda.edu.cn; zhangzq2001@126.com; feng.shi@uii-ai.com

41

42 **Manuscript word count:** 4552

43

44

45

46

47

48 **Impact of brain frailty on complications and outcomes**  
49 **in acute ischemic stroke**

50 **ABSTRACT**

51 **BACKGROUND:** This study aimed to determine the association of brain frailty with acute  
52 complications and prognosis in patients with acute ischemic stroke (AIS) due to occlusion of  
53 large vessels in the anterior circulation, and to further assess its predictive value.

54 **METHODS AND RESULTS:** This multicenter, retrospective study included patients with  
55 AIS due to large vessel occlusion in the anterior circulation. All patients underwent MRI  
56 within seven days of stroke onset, measuring subcortical and cortical atrophy and  
57 leukoaraiosis as indicators of brain frailty. The study included 1,090 patients with a median  
58 age of 64 (interquartile range, 55–73) years and a median National Institutes of Health Stroke  
59 Scale (NIHSS) score of 9 (interquartile range, 4.5–15). Multivariable logistic regression  
60 analysis showed that independent risk factors for the unfavorable clinical outcome included:  
61 NIHSS score (OR, 1.17; 95% CI, 1.13–1.22), blood glucose (OR, 1.15; 95% CI, 1.04–1.26),  
62 infarct volume (OR, 1.32; 95% CI, 1.15–1.52), subcortical atrophy (OR, 1.27; 95% CI, 1.18–  
63 1.37), severe cortical atrophy (OR, 5.46; 95% CI, 1.71–17.45), and severe leukoaraiosis (OR,  
64 4.68; 95% CI, 1.93–11.31). However, brain frailty was not significantly associated with AIS  
65 complications (malignant cerebral edema, parenchymal hemorrhage). Including brain atrophy  
66 indicators in the model significantly improved its unfavorable clinical outcome predictive  
67 power (AUC increased from 0.762 to 0.822;  $p < 0.001$ ). The results remained stable in  
68 subgroup analyses across treatment modalities.

69 **CONCLUSIONS:** Brain frailty was significantly associated with the unfavorable clinical  
70 outcome but not with acute complications. Brain frailty indicators contributed to the  
71 predictive efficacy, regardless of treatment modality.

72

73 **Key Words:**

74 atrophy; cerebral edema; frailty; ischemic stroke; leukoaraiosis; prognosis

75

76 **Non-standard Abbreviations and Acronyms**

77 AIS, acute ischemic stroke

78 AUC, area under the receiver operating characteristic curve

79 CDFs, cumulative distribution functions

80 DWI, diffusion-weighted imaging

81 FLAIR, fluid-enhanced inversion recovery

82 mRS, modified Rankin Scale

83 NIHSS, National Institutes of Health Stroke Scale

84 ROC, receptor operating characteristic

85 T1WI, T1-weighted imaging

86 T2WI, T2-weighted imaging

87

88 **INTRODUCTION**

89 Frailty is a clinically recognizable state of reduced physiological reserves in which older  
90 adults are more likely to experience a state of poor homeostasis resolution after a stressful  
91 event, increasing the risk of adverse outcomes.<sup>1,2</sup> Acute ischemic stroke (AIS) represents a  
92 quintessential stressor event, with up to 28% of patients with stroke having pre-existing  
93 frailty on hospital admission.<sup>3</sup> The analysis of data from 483,033 participants in the UK  
94 Biobank revealed an association between physical frailty and health-related outcomes, which  
95 could be mediated by differences in brain structure.<sup>4</sup> These differences are primarily  
96 characterized by hyperintensity on MRI and lower subcortical grey matter volume.<sup>4</sup> These  
97 brain frailty indicators facilitate a more objective assessment than physical signs of frailty.

98 Evidence suggests indicators of brain frailty are important for stroke prognosis. Post hoc  
99 analyses of randomized controlled trials showed that CT-assessed indicators of brain frailty  
100 were associated with decreased functional independence in patients with AIS who received  
101 intravenous thrombolysis<sup>5</sup> or endovascular therapy<sup>6</sup>. However, studies using MRI-assessed  
102 indicators of cerebral small-vessel disease, such as lacunes, enlarged perivascular spaces, and  
103 white matter hyperintensities, indicated that they are not associated with functional  
104 outcomes.<sup>7, 8</sup> Therefore, the choice of indicators might affect findings when assessing the  
105 relationship between brain atrophy and prognosis. Furthermore, it is unknown whether brain  
106 frailty has a differential effect on acute complications and functional outcome at 90 days.

107 Various factors influence AIS prognosis. Commonly used indicators to assess stroke  
108 complications and functional prognosis include age, National Institutes of Health Stroke  
109 Scale (NIHSS) score, infarct volume, blood glucose, and comorbidities.<sup>9-11</sup> Clinicians  
110 combine multiple variables in their clinical decision-making process when treating individual  
111 patients. However, few studies have used indicators of brain frailty as an important  
112 component in predicting outcomes. Moreover, whether brain frailty enhances models'  
113 predictive power remains unknown.

114 This multicenter, retrospective study analyzed real-world patients with AIS caused by  
115 anterior circulation large-vessel occlusion who received various treatment modalities. The  
116 selected indicators of brain frailty included subcortical and cortical atrophy and leukoaraiosis,  
117 which can be obtained by simple measurements on CT and MRI scans and are suitable for  
118 use in prospective clinical applications. This study aimed to 1) assess the association between  
119 brain frailty indicators and AIS complications (malignant cerebral edema, parenchymal  
120 hemorrhage) and unfavorable functional outcomes at 90 days and 2) assess the ability of  
121 brain frailty indicators to predict outcomes and increase predictive efficacy.

122

## 123 **METHODS**

124 This study was approved by the local ethics committees of all participating institutions  
125 (2024DZKY-019-01). The requirement for informed consent was waived by the local ethics  
126 committees. We followed the Standards for the Reporting of Diagnostic Accuracy Studies  
127 (STARD) guidelines for study execution and reporting (Supplemental Material). Data  
128 underpinning the findings of this study can be obtained from the corresponding author upon a  
129 reasonable request.

130

### 131 **Study population**

132 This multicenter, retrospective, observational cohort study used data from five centers. We  
133 considered consecutive patients presenting with AIS due to large-vessel occlusion in the  
134 anterior circulation treated between May 2018 and June 2023. The inclusion criteria were (1)  
135 adult patients (aged  $\geq 18$  years); (2) underwent MRI within seven days of admission; (3)  
136 presence of anterior circulation vessel occlusion (internal carotid or middle cerebral artery  
137 M1 or M2); (4) the 90-day modified Rankin Scale (mRS) score was not missing. Patients  
138 were excluded if they underwent the MRI beyond seven days or had an intracranial tumor,  
139 AIS in the posterior circulation or anterior cerebral artery supply area, severe artifacts,  
140 considerable midline shift, and segmentation failure that made it impossible to measure the  
141 infarct volume.

142

### 143 **Clinical assessment and outcomes**

144 We retrieved demographic, clinical, laboratory, and imaging data from the electronic medical  
145 record, including information on the patient's age and sex, comorbidities such as  
146 hypertension and diabetes mellitus, history of atrial fibrillation and stroke, and the NIHSS

147 score at admission. Laboratory values included blood glucose, glycated hemoglobin,  
148 low-density lipoprotein, high-density lipoprotein, and total cholesterol on admission.

149 The primary outcome was the 90-day functional outcome, assessed using the mRS,  
150 obtained by clinical follow-up or a telephone call. The mRS is an ordinal scale used to  
151 measure the degree of disability in daily activities. It ranges from 0 (no symptoms) to 6  
152 (death).<sup>12</sup> An mRS of 3 to 6 was defined as an unfavorable clinical outcome. The secondary  
153 outcomes were malignant cerebral edema and parenchymal hemorrhage. Malignant cerebral  
154 edema was defined as a large occupying infarct in the middle cerebral artery compressing the  
155 ventricles or causing midline shift of  $\geq 5$  mm, consciousness level of  $\geq 1$  on item 1a of the  
156 NIHSS, and no other causes of neurological deterioration.<sup>13</sup> Parenchymal hemorrhage was  
157 determined based on follow-up imaging and following the European Cooperative Acute  
158 Stroke Study II criteria.<sup>14</sup>

159

## 160 **Image acquisition**

161 MRI scans are part of routine clinical care. Since data were collected retrospectively from  
162 several clinical facilities, we could not ensure uniform scanner type, scanned area, and  
163 scanning protocol. Images were acquired using a 1.5-T or 3-T scanner (GE Discovery  
164 MR750 3T, Philips Ingenia 3T, Siemens Skyra 3T or Siemens Avanto 1.5T). The scanning  
165 sequences included T2-weighted imaging (T2WI), T1-weighted imaging (T1WI),  
166 fluid-enhanced inversion recovery (FLAIR), and diffusion-weighted imaging (DWI)  
167 sequences. The parameters of MRI acquisition were detailed in Supplementary Table S1.

168

## 169 **Image analysis**

## 170 **Brain frailty assessment**

171 Brain frailty (subcortical and cortical atrophy and leukoaraiosis) was assessed on T1WI,  
172 T2WI, or FLAIR sequence. The assessment included the contralateral cerebral hemisphere to  
173 avoid confusion due to the acute stroke.

174 Subcortical atrophy was measured by a senior radiologist with 15 years of experience  
175 (\*\*\*) who were blinded to the clinical information. Subcortical atrophy was assessed by  
176 calculating the ratio between the inter-caudate distance and the inner table width.<sup>15,16</sup> The  
177 inter-caudate distance was defined as the minimum distance between the head of the caudate  
178 nucleus and the septum lucidum at the level of the foramen of Monroe, multiplied by 2. The  
179 distance was measured in the contralateral hemisphere to avoid errors due to infarct-related  
180 edema.

181 Cortical atrophy and leukoaraiosis were assessed by two radiologists with six years of  
182 neuroimaging experience (\*\* and \*\*\*) who were blinded to the clinical information.  
183 Disagreements were resolved by a senior radiologist with fifteen years of experience (\*\*\*).  
184 Cortical atrophy was assessed using the global cortical atrophy scale, which evaluates the  
185 degree of cortical atrophy by assessing the sulcus's width and the gyrus's volume. The scale  
186 ranges from 0 (no atrophy) to 3 (severe atrophy).<sup>17</sup> Leukoaraiosis was visually assessed for  
187 periventricular and deep white matter lesions and a 3-level scale was used to classify  
188 whole-brain leukoaraiosis: none or mild (score 0-1), moderate (score 2), and severe (score  
189 3).<sup>18,19</sup>

190

### 191 **Infarct volume assessment**

192 An acute infarct segmentation model was established based on the VB-Net structure to  
193 automatically segment the whole lesion area on DWI with a b-value of 1,000 s/mm<sup>2</sup> and with  
194 apparent diffusion coefficient map reconstruction images. The automatic segmentation  
195 sequence was as follows: 1) Extract the brain tissue from the DWI image to reduce the



196 interference caused by the skull and other parts of the image; 2) normalize the extracted brain  
197 tissue so that the image grey scale range will be [0, 1]; 3) use the pre-processed image above  
198 as the input to the cascade neural network, and perform step-by-step coarse and fine  
199 segmentation of the DWI brain image; 4) obtain the lesion segmentation results based on  
200 voxel analysis. Two neuroradiologists with six years of neuroimaging experience proofread  
201 the automatic segmentation results (\*\* and \*\*\*).

202

### 203 **Statistical analysis**

204 Categorical variables are presented as counts (percentages) and were compared using the  $\chi^2$   
205 test. Continuous variables are presented as median (interquartile range, IQR) or mean  
206 (standard deviation, SD) based on their distribution, evaluated with the Shapiro-Wilk test,  
207 and compared using the Mann-Whitney  $U$  test or  $t$ -test, as appropriate.


208       Multivariate logistic regression, adjusted for age, sex, NIHSS score, and infarct volume,  
209 helped determine whether brain frailty was associated with acute complications and  
210 unfavorable 90-day clinical outcomes. We also performed subgroup analysis after dividing  
211 the patients based on the treatment modality received. The area under the receiver operating  
212 characteristic (ROC) curve (AUC) was used to assess the ability of individual variables at  
213 baseline, including the NIHSS score, infarct volume, baseline glucose, and subcortical  
214 atrophy, to predict unfavorable clinical outcomes. The AUC was combined with the  
215 multivariate variables to assess whether the brain atrophy indicators could predict  
216 unfavorable clinical outcome with a significant potentiating effect. The DeLong test  
217 compared the AUC of various variables. Statistical significance was set at  $p < 0.05$ .  
218 Statistical analysis was performed using R (<https://www.r-project.org>; The R Foundation) and  
219 EmpowerStats (<https://www.empowerstats.com>; X&Y Solutions, Inc).

220

221 **RESULTS**

222 **Baseline patient characteristics**

223 Among the 1,337 consecutively included patients with AIS due to acute large-vessel  
224 occlusion in the anterior circulation, 247 were considered ineligible (Figure 1): the MRI  
225 examination was performed more than seven days after admission in 92 patients; 5 patients  
226 had brain tumors; 39 patients had regional strokes in the vertebral basilar, posterior cerebral,  
227 or anterior cerebral artery; 24 patients had severe artifacts; 45 patients were missing the  
228 T1WI sequence; 11 patients had extensive midline shift; DWI volume calculation failed in 31  
229 patients.



230

231 **Figure 1. Patient selection flowchart.**

232 Abbreviation: CC/IT, intercaudate distance to inner table width;GCA, global cortical atrophy score

233

234 The median age of the remaining 1,090 participants was 64 (IQR, 55–73) years, and 754  
235 (69.2%) were male. Endovascular treatment was given to 443 patients (40.6%), intravenous  
236 thrombolysis to 143 (13.1%), and medical therapy to 504 (46.3%). The median NIHSS score  
237 was 9 (IQR, 4.50–14.00), and the median infarct volume was 13.42 (IQR, 4.33–44.45) mL.

238 Parenchymal hemorrhage was detected in 122 patients (11.2%), malignant cerebral edema in  
239 42 (3.9%), and unfavorable 90-day clinical outcomes in 435 (39.9%).

240 A comparison of the data for patients with favorable and unfavorable clinical outcomes  
241 is shown in Table 1. Patients with unfavorable clinical outcomes had higher median age [67  
242 (IQR, 58–75) vs. 62 (IQR, 52–70) years;  $p < 0.001$ ], NIHSS score [13 (IQR, 8–17) vs. 7  
243 (IQR, 3–12);  $p < 0.001$ ], and infarct volume [26.08 (IQR, 7.44–101.13) vs. 10.12 (IQR, 3.51–  
244 26.37) mL;  $p < 0.001$ ] than patients with favorable clinical outcomes. For brain atrophy  
245 indicators, patients with unfavorable clinical outcomes had more severe median subcortical  
246 atrophy [0.13 (IQR, 0.11–0.15) vs. 0.11 (IQR, 0.09–0.13);  $P < 0.001$ ], severe cortical atrophy  
247 rate (8.51% vs. 1.98% ;  $p < 0.001$ ), and Fazekas scores of 3 (12.64% vs. 3.97% ;  $p < 0.001$ )  
248 than those with favorable clinical outcomes.

249 **Table 1. Clinical and imaging characteristics of the patient population**

Characteristic	All participants (n = 1090)	Favorable outcome (mRS 0–2, n = 655)	Unfavorable outcome (mRS 3–6, n = 435)	P-value
Age, y, median (IQR)	64.00 (55.00-73.00)	62.00 (52.00-70.00)	67.00 (58.00-75.00)	<0.001
Sex, male, n (%)	754 (69.2%)	479 (73.1%)	275 (63.2%)	<0.001
Baseline NIHSS, median (IQR)	9.00 (4.50-14.00)	7.00 (3.00-12.00)	13.00 (8.00-17.00)	<0.001
Infarction volume, median (IQR), mL	13.42 (4.33-44.45)	10.12 (3.51-26.37)	26.08 (7.44-101.13)	<0.001
<b>Laboratory data</b>				
Blood glucose, median (IQR), mmol/L	5.73 (4.88-7.33)	5.40 (4.70-7.00)	6.40 (5.18-8.08)	<0.001
HbA1c, median (IQR), %	5.90 (5.50-6.90)	5.80 (5.45-7.00)	5.90 (5.50-6.80)	0.442
Total cholesterol, median (IQR), mmol/L	4.24 (3.62-4.98)	4.21 (3.62-5.01)	4.29 (3.62-4.91)	0.587
LDL, median (IQR), mmol/L	2.48 (1.93-3.14)	2.48 (1.94-3.13)	2.50 (1.92-3.16)	0.316
HDL, median (IQR), mmol/L	1.04 (0.88-1.24)	1.03 (0.87-1.23)	1.04 (0.89-1.27)	0.581
<b>Brain frailty</b>				
CC/IT ratio, median (IQR)	0.12 (0.10-0.14)	0.11 (0.09-0.13)	0.13 (0.11-0.15)	<0.001
Global cortical atrophy score				<0.001
0-1	754 (69.2%)	516 (78.8%)	238 (54.7%)	
2	286 (26.2%)	126 (19.2%)	160 (36.8%)	
3	50 (4.6%)	13 (2.0%)	37 (8.5%)	
Fazekas score				<0.001
0-1	706 (64.8%)	488 (74.5%)	218 (50.1%)	
2	303 (27.8%)	141 (21.5%)	162 (37.2%)	
3	81 (7.4%)	26 (4.0%)	55 (12.6%)	

<b>Comorbidities</b>				
Hypertension, n (%)	688 (63.2%)	409 (62.4%)	279 (64.3%)	0.537
Diabetes, n (%)	229 (21.0%)	136 (20.8%)	93 (21.4%)	0.792
Atrial fibrillation, n (%)	166 (15.3%)	81 (12.4%)	85 (19.6%)	0.001
Previous stroke, n (%)	62 (5.7%)	33 (5.0%)	29 (6.7%)	0.256
<b>Treatment</b>				<0.001
Medical therapy, n (%)	504 (46.2%)	342 (52.2%)	162 (37.2%)	
Endovascular therapy, n (%)	443 (40.6%)	250 (38.2%)	193 (44.4%)	
Intravenous thrombolysis, n (%)	143 (13.1%)	63 (9.6%)	80 (18.4%)	

250 Abbreviations: CC/IT, intercaudate distance to inner table width; IQR, 25th–75th percentile; LDL, low-density  
 251 lipoprotein; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; HbA1c, glycated  
 252 hemoglobin; HDL, high-density lipoprotein  
 253

## 254 Association of brain frailty with complications and outcomes

255 Multivariate logistic regression models adjusted for age, sex, NIHSS score, and infarct  
 256 volume are shown in Table 2. For malignant cerebral edema, NIHSS score (OR, 1.13; 95%  
 257 CI, 1.07–1.20;  $p < 0.001$ ), blood glucose (OR, 1.30; 95% CI, 1.12–1.51;  $p < 0.001$ ), and  
 258 infarct volume (OR, 1.67; 95% CI, 1.24–2.25;  $p < 0.001$ ) were independent risk factors ,  
 259 while subcortical atrophy, cortical atrophy, and leukoaraiosis were not (Table 2). For  
 260 parenchymal hemorrhage, NIHSS score (OR, 1.08; 95% CI, 1.03–1.12;  $p < 0.001$ ) and infarct  
 261 volume (OR, 1.67; 95% CI, 1.38–2.02;  $p < 0.001$ ) were independent risk factors, whereas  
 262 none of the remaining variables were significantly associated (Table 2).

263 For unfavorable clinical outcomes, NIHSS score (OR, 1.17; 95% CI, 1.13–1.22;  $p <$   
 264 0.001), blood glucose (OR, 1.15; 95% CI, 1.04–1.26;  $p = 0.005$ ), infarct volume (OR, 1.32;  
 265 95% CI, 1.15–1.52;  $p = 0.001$ ), subcortical atrophy (OR, 1.27; 95% CI, 1.18–1.37;  $p < 0.001$ ),  
 266 severe cortical atrophy (OR, 5.46; 95% CI, 1.71–17.45,  $p = 0.004$ ), and Fazekas score of 3  
 267 (OR, 4.68; 95% CI, 1.93–11.31;  $p = 0.001$ ) were independent predictors of unfavorable  
 268 clinical outcomes.

269


270 **Table 2. Multivariate logistic regression models for complications and unfavorable outcomes**

Variable	Malignant cerebral edema		Parenchymal hemorrhage		Unfavorable outcome	
	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Age, y	1.01 (0.97, 1.05)	0.624	1.02 (0.99, 1.05)	0.121	0.99 (0.97, 1.00)	0.078
Sex, male	1.18 (0.48, 2.85)	0.720	0.96 (0.55, 1.69)	0.895	0.48 (0.30, 0.76)	0.002
Baseline NIHSS	1.13 (1.07, 1.20)	<0.001	1.08 (1.03, 1.12)	<0.001	1.17 (1.13, 1.22)	<0.001
Infarction volume	1.67 (1.24, 2.25)	<0.001	1.67 (1.38, 2.02)	<0.001	1.32 (1.15, 1.52)	0.001
Blood glucose	1.30 (1.12, 1.51)	<0.001	1.06 (0.95, 1.18)	0.312	1.15 (1.04, 1.26)	0.005
CC/IT ratio	0.60 (0.15, 2.32)	0.457	1.02 (0.42, 2.46)	0.969	1.27 (1.18, 1.37)	<0.001
Global cortical atrophy						
0-1	Reference		Reference		Reference	
2	0.64 (0.23, 1.78)	0.394	1.02 (0.53, 1.96)	0.963	2.28 (1.36, 3.83)	0.002
3	0.75 (0.08, 7.07)	0.805	1.51 (0.46, 5.00)	0.501	5.46 (1.71, 17.45)	0.004
Fazekas score						
0-1	Reference		Reference		Reference	
2	0.81 (0.28, 2.33)	0.701	0.63 (0.32, 1.22)	0.173	2.09 (1.30, 3.35)	0.002
3	0.87 (0.17, 4.53)	0.868	1.04 (0.38, 2.87)	0.936	4.68 (1.93, 11.31)	0.001

271 Abbreviations: CC/IT, intercaudate distance to inner table width; mRS, modified Rankin Scale; NIHSS,  
272 National Institutes of Health Stroke Scale. Adjusted for age, sex, NIHSS score, and infarct volume.  
273


274 The cumulative distribution functions (CDFs) of brain frailty indicators associated with  
275 adverse clinical outcomes are shown in Figure 2. The CDFs illustrate that the cumulative  
276 probability of unfavorable clinical outcomes increases with the severity of subcortical  
277 atrophy (Figure 2A), cortical atrophy (Figure 2B), and leukoaraiosis (Figure 2C). The  
278 distribution of 90-day mRS scores for indicators of brain frailty is shown in Figure 3.

279



280

281 **Figure 2. Cumulative distribution functions (CDFs) of brain frailty indicators with unfavorable**  
 282 **clinical outcome (modified Rankin scale score 3–6).** A–C In all patients with acute ischaemic stroke, the  
 283 CDFs illustrate that the cumulative probability of unfavorable clinical outcomes increases with the severity of  
 284 subcortical atrophy(CC/IT ratio) (A), cortical atrophy (global cortical atrophy score) (B), and leukoaraiosis  
 285 (Fazakes score)(C). D–F Subgroup analysis of different treatments to assess the cumulative probability  
 286 distribution of subcortical atrophy (D), cortical atrophy (E) and leukoaraiosis (F) with unfavorable clinical  
 287 outcome. Abbreviation: CC/IT, intercaudate distance to inner table width.



288

289 **Figure 3. Distribution of 90-day mRS score for each indicator of brain frailty.**

290 A Distribution of 90-day mRS scores for subcortical atrophy (CC/IT ratio trisection); B Distribution of 90-day  
291 mRS scores for cortical atrophy (3-level score); C Distribution of 90-day mRS scores for leukoaraiosis (Fazekas  
292 score). Abbreviations: CC/IT, intercaudate distance to inner table width; mRS, modified Rankin Scale.


293

## 294 ROC analysis for unfavorable clinical outcome

295 Univariable ROC analysis determined the AUCs for subcortical atrophy (0.655; 95% CI,  
296 0.622–0.688), infarct volume (0.665; 95% CI, 0.632–0.699), blood glucose (0.623; 95% CI,  
297 0.586–0.660), and NIHSS score (0.724; 95% CI, 0.694–0.754) (Supplementary Table S2).

298 The diagnostic power of the NIHSS score was statistically better than that of infarct volume  
299 (DeLong test;  $p = 0.002$ ) and subcortical atrophy ( $p = 0.003$ ); infarct volume and subcortical  
300 atrophy had comparable predictive efficacy for unfavorable clinical outcomes ( $p = 0.609$ ).

301 The unfavorable clinical outcome prediction model (model 1) developed with age, sex,  
302 NIHSS score, blood glucose, and infarct volume showed discriminatory power with an AUC  
303 of 0.762 (95% CI, 0.731–0.793), sensitivity of 64.0%, and specificity of 75.9%. The AUC of  
304 the model 1 increased significantly when brain atrophy indicators were included (Model 2;  
305 0.822; 95% CI, 0.796–0.849; DeLong test;  $p < 0.001$ ; Figure 4).




**Figure 4. Receiver operating characteristic curves for predicting unfavorable clinical outcomes.**

Model 1: Age + Sex + NIHSS + Blood glucose + Infarction volume; Model 2: Model 1 + CC/IT ratio + GCA + Fazekas scores. Abbreviations: CC/IT, intercaudate distance to inner table width; GCA, global cortical atrophy score; NIHSS, National Institutes of Health Stroke Scale.

319

320 Subgroup analysis was conducted by treatment type, showing an increase in the AUC  
 321 from Model 1 to Model 2 in all. For patients receiving endovascular treatment, the AUCs of  
 322 Models 1 and 2 were 0.740 (95% CI, 0.686–0.793) and 0.872 (95% CI, 0.835–0.909),  
 323 respectively. The respective AUCs for patients receiving medical therapy were 0.756 (95%  
 324 CI, 0.710–0.802) and 0.812 (95% CI, 0.772–0.852). The respective AUCs for patients  
 325 receiving intravenous thrombolysis were 0.849(95% CI, 0.781–0.917) and 0.888 (95% CI,  
 326 0.826–0.950) ( Figure 5).



327  
 328 **Figure 5. Receiver operating characteristic curves predicting unfavourable clinical**  
 329 **outcomes (stratified analysis of treatment modalities).**

330 Model 1: Age+Sex+NIHSS+Blood glucose + Infarction volume; Model 2: Model 1+CC/IT ratio+GCA+Fazekas  
 331 scores. Abbreviations: CC/IT, intercaudate distance to inner table width; GCA, global cortical atrophy score;  
 332 mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

### 334 DISCUSSION

335 This multicenter study identified 1,090 patients with AIS due to large-vessel occlusion of the  
 336 anterior circulation and assessed the impact of brain atrophy indicators on acute  
 337 complications and 90-day clinical outcomes. First, we confirm the prognostic values of  
 338 subcortical atrophy, cortical atrophy, and leukoaraiosis, which were independently associated



339 with unfavorable clinical outcomes. Second, quantitative measures of subcortical atrophy  
340 were comparable to infarct volume in predicting unfavorable clinical outcomes, and inclusion  
341 of brain atrophy indicators significantly improved the predictive power of the multivariate  
342 logistic regression models. In addition, no correlation was found between malignant cerebral  
343 edema or parenchymal hemorrhage secondary to AIS and brain atrophy. The results of this  
344 study highlight the importance of integrating brain atrophy into the clinical diagnostic  
345 predictions and therapeutic decision-making for patients with AIS and help understand the  
346 differential impact brain atrophy has on acute complications and long-term prognosis of  
347 stroke.

348 Brain atrophy reflects the resilience or vulnerability of the brain due to the accumulation  
349 of multiple chronic damages.<sup>20</sup> The present study confirmed the important prognostic value  
350 of cortical atrophy, subcortical atrophy, and leukoaraiosis, each independently associated  
351 with unfavorable clinical outcomes. The ESCAPE-NA1 trial included patients with  
352 endovascular thrombolysis. Patients with cortical and subcortical atrophy detected by visual  
353 assessment of acute CT images had a less favorable AIS recovery and worse 90-day  
354 functional prognosis than patients without brain atrophy.<sup>6</sup> A secondary analysis of that trial  
355 found that 85.1% of the association between age and 90-day functional outcomes after  
356 thrombectomy was mediated by brain frailty features, highlighting the importance of brain  
357 atrophy rather than chronological age alone in predicting stroke prognosis.<sup>16</sup> In the  
358 International Stroke Trial (IST-3), which included patients with ischemic stroke who  
359 underwent intravenous thrombolysis, pre-existing brain CT signs (old infarcts, leukoaraiosis,  
360 and atrophy) were associated with decreased functional independence and increased  
361 symptomatic intracranial hemorrhage.<sup>5</sup> The findings of our study, which included real-world  
362 patients with AIS receiving various treatment modalities, are consistent with the results  
363 described above, further demonstrating the importance of brain atrophy indicators for stroke

364 prognosis. Furthermore, the brain atrophy indicators chosen for this study took into account  
365 clinical feasibility and reproducibility and are easily detectable on CT or MRI scans.<sup>15</sup> The  
366 simple quantitative measurement of subcortical atrophy avoids the influence of the infarcted  
367 side of the brain, and visual assessment of cortical atrophy and leukoaraiosis is easy to  
368 perform without relying on any special software.

369 The prognostic predictive power of the model based on the remaining predictors of  
370 complications and unfavorable clinical outcomes found in our study, including age, NIHSS  
371 score, infarct volume, and blood glucose, improved significantly when combined with brain  
372 frailty indicators. Prognostic prediction models used in other studies relied on various  
373 variable combinations. For example, the THRIVE score included age, initial NIHSS score,  
374 and comorbidities.<sup>9</sup> The SPAN-100 index summed the patient's age and NIHSS score to  
375 predict clinical outcomes after intravenous and mechanical thrombolysis.<sup>11</sup> The PRE score  
376 model combined the patient's age, initial NIHSS score, and the Alberta Stroke Program Early  
377 Computed Tomography Score (ASPECTS) as continuous variables.<sup>10</sup> The MRI-DRAGON  
378 score, which includes clinical (age, NIHSS score, glucose level, pre-stroke disability, and  
379 onset-to-treatment time) and radiological (DWI-ASPECTS, M1 occlusion) variables, had a  
380 high specificity for predicting the prognosis.<sup>21</sup> None of these models included indicators of  
381 brain atrophy, and regardless of their complexity, their discriminative performance ranged  
382 between 0.73 and 0.83.<sup>9,10,11,21</sup> A recent study showed that adding cortical atrophy and  
383 age-related white matter changes led to a small but significant improvement in machine  
384 learning-based clinical outcome prediction models, increasing the AUC from 0.763 to  
385 0.775.<sup>22</sup> The present study used conventional variables and traditional logistic regression  
386 methods, achieving a significant increase in the AUC for predicting unfavorable clinical  
387 outcomes from 0.762 to 0.822 ( $p < 0.001$ ) when including the brain atrophy indicators. The  
388 results remained stable in the treatment modality-based subgroup analyses.

389           Interesting differences in the correlation of brain atrophy with acute complications and  
390 functional recovery at 90 days were noted. The idea that brain atrophy might act as a buffer  
391 against acute stroke-induced brain swelling and occupancy effects has been previously  
392 suggested.<sup>23,24</sup> A recent study investigated the effect of brain atrophy on the outcomes after  
393 endovascular treatment in 295 patients with AIS using visual scores and the Evans index (the  
394 ratio between the maximum widths of the frontal horns of the lateral ventricles and the  
395 maximal internal diameter of the skull at the same level). They found a positive association  
396 between the risk of futile reperfusion and atrophy; however, the Evans index does not  
397 account for underlying AIS-related edema or hemorrhage.<sup>23</sup> A post hoc analysis of the  
398 ENCHANTED trial showed that brain atrophy was associated with lower early mortality in  
399 patients with stroke, possibly because brain atrophy made them more tolerant to brain  
400 swelling; however, the loss of neuronal plasticity and recovery also led to poorer functional  
401 prognosis.<sup>24</sup> In our study, brain atrophy indicators did not significantly correlate with  
402 malignant brain edema or parenchymal hemorrhage, while the same indicators were risk  
403 factors for unfavorable 90-day functional outcomes. This difference indirectly reflects the  
404 different mechanisms through which brain atrophy affects acute complications and long-term  
405 prognosis. Clinical treatment decisions should take this difference into account.

406           The strengths of our study include the stability of the correlation between brain frailty  
407 and prognosis across various treatment modalities, and the difference between acute  
408 complications and 90-day prognosis in their correlation with brain frailty indicators.  
409 Moreover, the brain frailty indicators selected for this study are easy to measure and suitable  
410 for use in acute stroke settings and prospective studies. This study had some limitations: 1.  
411 Lack of finer segmentation and measurement of cortical and subcortical atrophy. In the  
412 absence of quantitative measurements of the leukoaraiosis volume, we used the Fazekas scale.  
413 2. Some indicators of cerebral small vessel disease, such as microhemorrhages, lacunae, and

414 enlarged perivascular spaces, were not assessed, given the commonality of the indicators  
415 between CT and MRI assessments. 3. The small number of patients receiving IV  
416 thrombolysis may have biased the study finding. 4. The model in this study obtained the  
417 prediction results for unfavorable clinical outcome through multivariate logistic regression  
418 analysis; because of the lack of cross-validation, it is possible that the results of the model are  
419 overly optimistic.

420 In conclusion, the present study suggests that brain frailty indices are strong independent  
421 prognostic predictors of AIS due to large-vessel occlusion; however, they are not associated  
422 with acute complications. These findings have important implications for guiding patients'  
423 acute treatment and functional recovery. Brain frailty indicators significantly enhanced the  
424 prediction of patient prognosis. The selection of simple, easy-to-measure indicators of brain  
425 frailty that can be easily integrated into existing predictive models could support prospective  
426 therapeutic decision-making.

427

#### 428 **Acknowledgments**

429 None

430

#### 431 **Sources of Funding**

432 This research was funded by the National Natural Scientific Foundation of China  
433 (82271983).

434

#### 435 **Disclosures**

436 All authors have read and approved the submitted manuscript, the manuscript has not been  
437 submitted elsewhere nor published elsewhere in whole or in part. There are no any ethical or  
438 legal conflicts involved in this manuscript.

## 439 **References**

- 440 1. Evans NR, Todd OM, Minhas JS, Fearon P, Harston GW, Mant J, Mead G, Hewitt J, Quinn TJ,  
441 Warburton EA. Frailty and cerebrovascular disease: Concepts and clinical implications for stroke  
442 medicine. *Int J Stroke*. 2022 ;17:251-259. doi: 10.1177/17474930211034331
- 443 2. Kim DH, Rockwood K. Frailty in Older Adults. *N Engl J Med*. 2024;391:538-548. doi:  
444 10.1056/NEJMra2301292. PMID: 39115063.
- 445 3. Taylor-Rowan M, Hafdi M, Drozdowska B, Elliott E, Wardlaw J, Quinn TJ. Physical and brain  
446 frailty in ischaemic stroke or TIA: Shared occurrence and outcomes. A cohort study. *Eur Stroke J*.  
447 2023 ;8:1011-1020. doi: 10.1177/23969873231186480
- 448 4. Jiang R, Noble S, Sui J, Yoo K, Rosenblatt M, Horien C, Qi S, Liang Q, Sun H, Calhoun VD, et al.  
449 Associations of physical frailty with health outcomes and brain structure in 483 033 middle-aged  
450 and older adults: a population-based study from the UK Biobank. *Lancet Digit Health*.  
451 2023;5:e350-e359. doi: 10.1016/S2589-7500(23)00043-2
- 452 5. IST-3 collaborative group. Association between brain imaging signs, early and late outcomes, and  
453 response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial  
454 (IST-3): secondary analysis of a randomised controlled trial. *Lancet Neurol*. 2015 ;14:485-96. doi:  
455 10.1016/S1474-4422(15)00012-5
- 456 6. Benali F, Fladt J, Jaroengarmsamer T, Bala F, Singh N, Ospel JM, Tymianski M, Hill MD, Goyal  
457 M, Ganesh A. Association of Brain Atrophy With Functional Outcome and Recovery Trajectories  
458 After Thrombectomy: Post Hoc Analysis of the ESCAPE-NA1 Trial. *Neurology*.  
459 2023 ;101:e1521-e1530. doi: 10.1212/WNL.0000000000207700
- 460 7. Bu N, Khelif MS, Lemmens R, Wouters A, Fiebach JB, Chamorro A, Ringelstein EB, Norrving B,  
461 Laage R, Grond M, et al. Imaging Markers of Brain Frailty and Outcome in Patients With Acute  
462 Ischemic Stroke. *Stroke*. 2021;52:1004-1011. doi: 10.1161/STROKEAHA.120.029841
- 463 8. Arba F, Inzitari D, Ali M, Warach SJ, Luby M, Lees KR; STIR/VISTA Imaging Collaboration.  
464 Small vessel disease and clinical outcomes after IV rt-PA treatment. *Acta Neurol Scand*.  
465 2017;136:72-77. doi: 10.1111/ane.12745

- 466 9. Flint AC, Rao VA, Chan SL, Cullen SP, Faigeles BS, Smith WS, Bath PM, Wahlgren N, Ahmed N,  
467 Donnan GA, et al. Improved ischemic stroke outcome prediction using model estimation of  
468 outcome probability: the THRIVE-c calculation. *Int J Stroke*. 2015;10:815-21. doi:  
469 10.1111/ijvs.12529
- 470 10. angaraju S, Aghaebrahim A, Streib C, Sun CH, Ribo M, Muchada M, Nogueira R, Frankel M,  
471 Gupta R, Jadhav A, et al. Pittsburgh Response to Endovascular therapy (PRE) score: optimizing  
472 patient selection for endovascular therapy for large vessel occlusion strokes. *J Neurointerv Surg*.  
473 2015;7:783-8. doi: 10.1136/neurintsurg-2014-011351
- 474 11. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke Prognostication using Age  
475 and NIH Stroke Scale: SPAN-100. *Neurology*. 2013 ;80:21-8. doi:  
476 10.1212/WNL.0b013e31827b1ace
- 477 12. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for  
478 the assessment of handicap in stroke patients. *Stroke*.1988;19:604-7. doi: 10.1161/01.str.19.5.604
- 479 13. Irvine HJ, Ostwaldt AC, Bevers MB, Dixon S, Battey TW, Campbell BC, Davis SM, Donnan GA,  
480 Sheth KN, Jahan R,et al. Reperfusion after ischemic stroke is associated with reduced brain edema.  
481 *J Cereb Blood Flow Metab*. 2018;38:1807-1817. doi: 10.1177/0271678X17720559
- 482 14. Larrue V, von Kummer R R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic  
483 transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a  
484 secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). *Stroke*.  
485 2001;32:438-41. doi: 10.1161/01.str.32.2.438
- 486 15. Jaroengarmsamer T, Benali F, Fladt J, Singh N, Bala F, Tymianski M, Hill MD, Goyal M, Ganesh  
487 A; ESCAPE-NA1 Investigators. Cortical and Subcortical Brain Atrophy Assessment Using  
488 Simple Measures on NCCT Compared with MRI in Acute Stroke. *AJNR Am J Neuroradiol*.  
489 2023;44:1144-1149.doi: 10.3174/ajnr.A7981
- 490 16. Benali F, Singh N, Fladt J, Jaroengarmsamer T, Bala F, Ospel JM, Buck BH, Dowlatshahi D,  
491 Field TS, Hanel RA, et al. Mediation of Age and Thrombectomy Outcome by Neuroimaging  
492 Markers of Frailty in Patients With Stroke. *JAMA Netw Open*. 2024 ;7:e2349628. doi:  
493 10.1001/jamanetworkopen.2023.49628

- 494 17. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver  
495 reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. *Eur Neurol.*  
496 1996;36:268-72. doi: 10.1159/000117270
- 497 18. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in  
498 Alzheimer's dementia and normal aging. *AJR Am J Roentgenol.* 1987;149:351-6. doi:  
499 10.2214/ajr.149.2.351
- 500 19. Oveisgharan S, Yu L, Poole VN, Evia AM, Barnes LL, Schneider JA, Arfanakis K, Bennett DA,  
501 Buchman AS. Association of White Matter Hyperintensities With Pathology and Progression of  
502 Parkinsonism in Aging. *JAMA Neurol.* 2021 ;78:1494-1502. doi: 10.1001/jamaneurol.2021.3996
- 503 20. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity  
504 and implications for health care, research, and medical education: a cross-sectional study. *Lancet.*  
505 2012;380:37-43. doi: 10.1016/S0140-6736(12)60240-2
- 506 21. Ben Hassen W, Raynaud N, Bricout N, Boulouis G, Legrand L, Ferrigno M, Kazemi A, Bretzner M,  
507 Soize S, Farhat W, et al. MT-DRAGON score for outcome prediction in acute ischemic stroke  
508 treated by mechanical thrombectomy within 8 hours. *J Neurointerv Surg.* 2020;12:246-251. doi:  
509 10.1136/neurintsurg-2019-015105
- 510 22. Brugnara G, Engel A, Jesser J, Ringleb PA, Purrucker J, Möhlenbruch MA, Bendszus M,  
511 Neuberger U. Cortical atrophy on baseline computed tomography imaging predicts clinical  
512 outcome in patients undergoing endovascular treatment for acute ischemic stroke. *Eur Radiol.*  
513 2024;34:1358-1366. doi: 10.1007/s00330-023-10107-2
- 514 23. Pedraza MI, de Lera M, Bos D, Calleja AI, Cortijo E, Gómez-Vicente B, Reyes J, Coco-Martín MB,  
515 Calonge T, Agulla J, et al. Brain Atrophy and the Risk of Futile Endovascular Reperfusion in Acute  
516 Ischemic Stroke. *Stroke.* 2020;51:1514-1521. doi: 10.1161/STROKEAHA.119.028511
- 517 24. Delcourt C, Wang X, Zhou Z, Wardlaw JM, Mair G, Robinson TG, Chen X, Yoshimura S,  
518 Torii-Yoshimura T, Carcel C, et al. Brain imaging abnormalities and outcome after acute ischaemic  
519 stroke: the ENCHANTED trial. *J Neurol Neurosurg Psychiatry.* 2020;91:1290-1296. doi:  
520 10.1136/jnnp-2020-323015

521 **Figure legends**

522

523 Figure 1. Patient selection flowchart.

524 Figure 2. Cumulative distribution functions (CDFs) of brain frailty indicators with  
525 unfavorable clinical outcome (modified Rankin scale score 3–6 ).


526 Figure 3. Distribution of 90-day mRS score for each indicator of brain frailty.







527 Figure 4. Receiver operating characteristic curves for predicting unfavorable clinical  
528 outcomes.




529 Figure 5. Receiver operating characteristic curves predicting unfavourable clinical outcomes  
530 (stratified analysis of treatment modalities).

531












**A****B****C**

mRS score





	AUC	95%CI	Specificity	Sensitivity	<i>P</i> value
<b>Model 1</b>	0.762	0.731-0.793	0.759	0.640	0.001
<b>Model 2</b>	0.822	0.796-0.849	0.729	0.742	



	Medical therapy			Endovascular therapy			Intravenous thrombolysis		
	Model 1	Model 2	<i>P</i> value	Model 1	Model 2	<i>P</i> value	Model 1	Model 2	<i>P</i> value
AUC	0.756	0.812	0.001	0.740	0.872	0.001	0.849	0.888	0.062
95%CI low	0.710	0.772		0.686	0.835		0.781	0.826	
95%CI upp	0.802	0.852		0.793	0.909		0.917	0.950	
Specificity	0.665	0.697		0.759	0.819		0.764	0.865	
Sensitivity	0.733	0.795		0.635	0.756		0.818	0.818	